The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

Thomas W. LeBlanc, MD, MA, discusses key clinical pearls for community oncologists in the treatment of anemia in patients with low-risk myelodysplastic syndromes (LR-MDS), including the importance of ...

Given all the treatment strategies and key updates discussed today, what are your overall thoughts on luspatercept in the LR-MDS treatment landscape? What clinical pearls can you leave for community ...

Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS ...

Request an Appointment Fred Hutch: A Leader in MDS Treatment Fred Hutch is recognized as a Center of Excellence by the Myelodysplastic Syndromes Foundation for the diagnosis and treatment of MDS. Our ...

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...

TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, has announced the identification of the final patient for its BEXMAB Phase II ...

Management of hematologic conditions including MDS and acute leukemias are particularly challenging among older adults due to variable coexisting comorbid conditions and functional status which can ...

Only a tiny percentage of people addicted to alcohol or drugs take medication for it. Why not? It's complicated, but the ...

A RECENT study has shed light on the particularly poor prognosis faced by patients who develop acute myeloid leukaemia (AML) after receiving treatment for myelodysplastic syndrome (MDS) or related ...

Geron filed imetelstat with the FDA last August as a treatment for transfusion-dependent anaemia in lower-risk MDS patients and is waiting for the outcome of the agency’s review, expected in mid ...